IL246540A0 - Freezeald receptor antibodies for cancer treatment - Google Patents

Freezeald receptor antibodies for cancer treatment

Info

Publication number
IL246540A0
IL246540A0 IL246540A IL24654016A IL246540A0 IL 246540 A0 IL246540 A0 IL 246540A0 IL 246540 A IL246540 A IL 246540A IL 24654016 A IL24654016 A IL 24654016A IL 246540 A0 IL246540 A0 IL 246540A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
receptor antibodies
frizzled receptor
frizzled
Prior art date
Application number
IL246540A
Other languages
English (en)
Hebrew (he)
Inventor
Benjamin Dekel
Naomi Pode Shakked
Orit Harari-Steinberg
Michal Mark-Danieli
Einav Vax
Original Assignee
Tel Hashomer Medical Res Infrastructure & Services Ltd
Univ Ramot
Benjamin Dekel
Naomi Pode Shakked
Harari Steinberg Orit
Mark Danieli Michal
Einav Vax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Res Infrastructure & Services Ltd, Univ Ramot, Benjamin Dekel, Naomi Pode Shakked, Harari Steinberg Orit, Mark Danieli Michal, Einav Vax filed Critical Tel Hashomer Medical Res Infrastructure & Services Ltd
Publication of IL246540A0 publication Critical patent/IL246540A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL246540A 2014-01-02 2016-06-30 Freezeald receptor antibodies for cancer treatment IL246540A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461922893P 2014-01-02 2014-01-02
PCT/IL2015/050009 WO2015101998A1 (en) 2014-01-02 2015-01-01 Frizzled receptor antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
IL246540A0 true IL246540A0 (en) 2016-08-31

Family

ID=53493369

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246540A IL246540A0 (en) 2014-01-02 2016-06-30 Freezeald receptor antibodies for cancer treatment

Country Status (6)

Country Link
US (1) US10465004B2 (cg-RX-API-DMAC7.html)
EP (1) EP3089995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017506214A (cg-RX-API-DMAC7.html)
CA (1) CA2935630A1 (cg-RX-API-DMAC7.html)
IL (1) IL246540A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015101998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer
WO2017100154A1 (en) * 2015-12-07 2017-06-15 Purdue Research Foundation Inhibitors for proliferating cell nuclear antigen and uses
CN112159474B (zh) * 2019-11-06 2021-11-19 上海健康医学院 一种靶向Frizzled7人源化抗体及其制备方法与应用
WO2026051924A1 (zh) * 2024-09-03 2026-03-12 浙江道尔生物科技有限公司 抗fzd7单域抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
EP2500360B1 (en) * 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2331136B1 (en) * 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer

Also Published As

Publication number Publication date
WO2015101998A1 (en) 2015-07-09
EP3089995A1 (en) 2016-11-09
CA2935630A1 (en) 2015-07-09
US20160326245A1 (en) 2016-11-10
EP3089995A4 (en) 2017-11-29
JP2017506214A (ja) 2017-03-02
US10465004B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
HUS2500001I1 (hu) Antitestkészítmények daganatkezelésre
IL265755A (en) A chimeric antibody receptor for cancer therapy
IL250043B (en) Chimeric anti–bcma humanized antigen receptor cancer therapy
IL247204A0 (en) Cancer treatment using a chimeric receptor antigen (car) against cd19
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
IL250161A0 (en) Ror1-specific chimeric antigen receptors (ntrkr1) for cancer immunotherapy
IL252232A0 (en) Tumor treatment methods using a bispecific antibody for CD3 and CD20
PT3063173T (pt) Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
IL285077A (en) Compounds for the treatment of cancer
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
DK3126390T3 (da) Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
IL251376A0 (en) Methods for assessing the risk of developing breast cancer
EP3191128A4 (en) Uses of anti-her3 antibodies for treating cancer
IL248391A0 (en) Methods for using anti-ang2 antibodies
SG11201701076TA (en) Diagnosis of cancer
EP3089995A4 (en) Frizzled receptor antibodies for treatment of cancer